Patents by Inventor Andrew M. Siwkowski
Andrew M. Siwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132885Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: December 2, 2022Publication date: April 25, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20230263822Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: January 5, 2023Publication date: August 24, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Patent number: 11535849Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: GrantFiled: June 1, 2020Date of Patent: December 27, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 11376273Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: GrantFiled: July 29, 2020Date of Patent: July 5, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20210169921Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: July 29, 2020Publication date: June 10, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20210095281Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: June 1, 2020Publication date: April 1, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20200000839Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: February 12, 2019Publication date: January 2, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20190169613Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: December 21, 2018Publication date: June 6, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20180273946Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: October 11, 2017Publication date: September 27, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9816092Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: GrantFiled: June 23, 2016Date of Patent: November 14, 2017Assignee: Ionis Phamaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9617540Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: April 28, 2015Date of Patent: April 11, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20170035798Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: March 21, 2016Publication date: February 9, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20160369275Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: June 23, 2016Publication date: December 22, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9428750Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: GrantFiled: February 20, 2015Date of Patent: August 30, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
-
Patent number: 9399774Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: GrantFiled: May 20, 2015Date of Patent: July 26, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20160010086Abstract: The present invention provides method of optimizing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.Type: ApplicationFiled: December 2, 2014Publication date: January 14, 2016Applicant: ISIS PHARMACEUTICALS, INC.Inventors: C. FRANK BENNETT, RICHARD S. GEARY, ERIC E. SWAYZE, ANDREW M. SIWKOWSKI
-
Publication number: 20150344879Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: April 28, 2015Publication date: December 3, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20150259681Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.Type: ApplicationFiled: February 20, 2015Publication date: September 17, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
-
Publication number: 20150252367Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: May 20, 2015Publication date: September 10, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9045754Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: May 7, 2007Date of Patent: June 2, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz